This was a prospective tissue collection study for gene expression profiling of 62 pretreatment biopsies from patients with advanced cervical cancer. Patients were treated with definitive radiation. Fifty-three patients received concurrent chemotherapy.
All patients underwent a pretreatment and a 3-month post therapy FDG-PET/CT.
Tumor RNA was harvested from fresh frozen tissue and hybridized to Affymetrix U133Plus2 GeneChips. Gene set enrichment analysis (GSEA) was used to identify signaling pathways associated with tumor metabolic response. Immunohistochemistry and in vitro FDG uptake assays were used to confirm our results.
Results
There were 40 biopsies from patients with a complete metabolic response (PET negative group) and 22 biopsies from patients with incomplete metabolic response (PET positive group). The 3-year cause-specific survival estimates were 98% for the PET negative group and 39% for the PET positive group (p<0.0001). GSEA identified alterations in expression of genes associated with the PI3K/Akt signaling pathway in patients with a positive follow up PET. Immunohistochemistry using a tissue microarray of 174 pretreatment biopsies confirmed pAkt as a biomarker for poor prognosis in cervical cancer. The PI3K inhibitor LY294002 inhibited FDG uptake in vitro in cervical cancer cell lines.
Conclusions
Activation of the PI3K/Akt pathway is associated with incomplete metabolic response in cervical cancer. Targeted inhibition of PI3K/Akt may improve response to chemoradiation. Therapeutic response as determined by post-therapy FDG-PET and more recently FDG-PET/CT, has been shown to be predictive of progression-free and overall survival outcomes. (4) (5) (6) In a prospective data collection study at our institution, 3-year cause-specific survival was 100% and 51% for patients with a complete versus a partial metabolic response on 3 month post therapy FDG-PET (p<0.001). Corresponding 3-year progression-free survivals were 78% and 35% (p<0.0001), respectively.
Multivariate analysis demonstrated that metabolic response was more predictive of treatment outcome than all known pretreatment related factors, including FIGO stage and lymph node status. Post-therapy FDG-PET may therefore be used as an immediately available surrogate biomarker for overall response to therapy.
Microarray analysis of tissue biopsy specimens has been widely implemented as a high throughput method for the detection of altered gene expression. With respect to cervical carcinoma, gene expression profiling has been used in several small studies to identify genes associated with poor outcome after treatment. Very few studies have explored the molecular mechanisms that regulate treatment response in cervical cancer, and no studies have specifically examined the signaling pathways that influence cervical tumor metabolic response. The objective of the current study was to use gene expression profiling as a discovery tool to identify signaling pathways associated with incomplete metabolic response after chemoradiation therapy in cervical cancer.
Materials and Methods:

Patients
The study population included 62 patients prospectively enrolled into a tumor banking protocol at the time of diagnosis of cervical cancer (March 1998 through December 2006). Eligibility criteria for tumor banking were: 1) patients had a pathologic diagnosis of invasive carcinoma of the cervix; 2)patient age was greater than or equal to 18 years; 3) patient's tumor had adequate tissue to obtain a 1 cm biopsy and 4) patients were scheduled to undergo radiation therapy with or without chemotherapy in the Department of Radiation Oncology at Washington University School of Medicine.
As part of the tumor banking protocol, tumor biopsies were obtained and frozen prior to the initiation of therapy. As part of standard practice at our institution, both pretreatment 
Clinical Follow Up
Clinical follow up was performed 6 weeks after the completion of therapy. Posttherapy FDG-PET was performed 3 months after the completion of therapy. Patients and 2 patients died due to toxicity. The remaining 36 patients had no evidence of disease.
PET Imaging
Before November 2002, FDG-PET was performed using a conventional PET scanner and interpreted as previously described. (13) Thereafter, all FDG-PET studies were performed with a hybrid PET/CT scanner using methods described by Wright et al. (14) For patients in this study, 24 were imaged with conventional PET and 38 were imaged with PET/CT. PET studies were deferred until the blood glucose concentration was less than 200 mg/dL. PET/CT images were interpreted in a standard clinical fashion, both separately and in a fused mode. Standardized uptake value (SUV max ) was determined for primary tumors from the pretreatment FDG-PET as previously Survival and tumor recurrence were measured from the completion of treatment.
The Kaplan-Meier (product-limit) method was used to derive estimates of survival, based on total sample size. StatView version 5.0.1 software (SAS Institute, Cary, NC) was used for the analysis. P< .05 was set as the threshold for significance for all study outcomes. Tests of equivalence of estimates of survival were performed by the generalized Wilcoxon log-rank test. A paired t-test was used to compare the results of pAkt staining to pretreatment cervix tumor standardized uptake value (SUV max ).
Gene Expression Profiling
Pretreatment tumor biopsies were frozen at the time of collection. Frozen sections were histologically reviewed for documentation of invasive cancer; only biopsies with > 25% tumor were included in this studyTumor RNA was harvested from fresh frozen tissue using Trizol reagent (Invitrogen, Carlsbad, CA) as described. (16) RNA samples were then labeled and hybridized to Affymetrix Human Genome U133 Plus 2.0 expression microarrays (Affymetrix, Santa Clara, CA) using standard protocols from the Laboratory for Clinical Genomics. (16, 17) To perform inter-array comparisons, the raw scan data from each microarray were scaled to a target intensity of 1500 using the Affymetrix GCOS 1.2 (MAS 5) statistical algorithm (http://www.affymetrix.com).
Basic microarray data visualization, data filtering and hierarchical clustering were performed using the Spotfire DecisionSite for Functional Genomics (Somerville, MA) as IHC results. The remaining 10 were uninterpretable due to artifact or detachment of the biopsy from the glass slide during processing.
Western blotting
Cervix cell lines SW756, Caski, C33A, C41, Me180, HeLa, HT-3 and SiHa were grown in standard media supplemented with fetal bovine serum to 70-80% confluence. Cells were washed twice with PBS and extracted in lysis buffer containing 1 % NaF, 0.5% Na 3 VO 4 , and protease inhibitor. Equal amounts of proteins from each sample were added in loading buffer and were heated for 3 min at 100°C. Samples were loaded on 10% SDS-PAGE gel for running 2 h and were then transferred onto Bio-Rad nitrocellulose membranes (Bio-Rad, CA).
After blocking for 1 h with 5% nonfat dry milk, blots were probed overnight at 4°C with primary antibodies against pAkt 
FDG uptake assays
Cervix cell lines SiHa, ME-180 and C33A were grown in media supplemented with fetal bovine serum to 70-80% confluence. Thirty minutes prior to adding radiolabeled glucose, media was changed to Glucose-free DMEM + 10% FBS. Cells 
, Danvers, MA). Cells were rinsed in cold PBS, harvested in 500 ul of 1% SDS + 10 mM Na borate and counted on a gamma counter.
Results:
Metabolic Response and Survival Outcome
There were 40 pretreatment biopsies from patients with no evidence of disease on the 3 month post-therapy PET (PET negative group) and 22 pretreatment biopsies from patients with residual or progressive disease on the 3 month post-therapy PET (PET positive group). The 3-year cause-specific survival estimates were 98% for the PET negative group and 39% for the PET positive group ( Figure 1A ). The corresponding 3-year progression-free survival estimates were 84% and 32%, respectively ( Figure 1B ).
Gene Expression Profiling
We examined global gene expression in cervical tumors as a means to identify signaling pathways whose up-or down-regulation correlated with tumor metabolic response, as demonstrated by 3-month post-therapy FDG-PET/CT. The patient population consisted of 62 women diagnosed with cervical cancer; see Table 1 tumors) based on these timeframes. Clinical characteristics were similar between the 2 groups ( Table 1 ).
The specific goal of the gene expression analysis was the identification of dysregulated signaling pathways associated with tumor metabolic response. Gene Set Enrichment Analysis (GSEA) (http://www.broad.mit.edu/gsea), a powerful bioinformatic tool that assesses whether an a priori defined set of genes (e.g., those in a common signaling pathway) shows statistically significant, concordant differences between two biological states (i.e. phenotypes). Therefore, we used GSEA to test whether the The net effect is a sigmoidal curve. The bottom portion of the plot shows the value of the ranking metric moving down the list of ranked genes. A positive ranking metric indicates that a gene is correlated with the PET positive phenotype. The table in Figure   2 enumerates the genes in the pathway for which a majority of probesets were significantly enriched and upregulated in PET positive versus PET negative tumors.
Note that members of the AKT, PI3K, and PTEN pathways are significantly enriched.
Immunohistochemistry
To test whether Akt pathway activation is associated with survival outcome in human cervical cancers at the protein level, we performed pAkt immunohistochemistry using a commercially available anti-pS473 antibody and a 
Glucose uptake assays
To test whether the PI3k/Akt pathway regulates glucose uptake in cervical cancer cells, we began by performing western blots for pAkt using 8 different 
Our previous clinical data demonstrated that cervical cancer patients with incomplete metabolic response after chemoradiation have poor survival outcome .(6) In the current study, we used GSEA and 62 fresh frozen pretreatment cervical cancer biopsies to identify signaling pathways that are associated with post-treatment metabolic response in cervical cancer. GSEA identified reproducible alterations in expression of genes from the PI3K/Akt signaling pathway in patients with incomplete metabolic response. To confirm these results at the protein level, we tested 174 archived paraffin embedded specimens for pAkt expression using immuohistochemistry.
Our results show that pretreatment pAkt expression is common in cervical cancer (88% pAkt positive). In the subset of patients with squamous cell histology, increased expression of pAkt was associated with decreased progression-free survival outcome after chemoradiation. In addition, increased expression of pAkt was associated with increased glucose uptake on the pretreatment FDG-PET, suggesting that pAkt expression is associated with tumor glucose uptake in vivo.
The PI3K/Akt signaling pathway is known to be dysregulated in several cancer sites, most notably endometrium where loss of PTEN and mutations of PIK3CA have been reported. For cervical cancer, a detailed analysis of the PI3K/Akt pathway using human tumor samples is lacking; however, the cumulative results of several small studies suggest that the PI3K/Akt pathway is activated in cervical cancer. In a Norwegian study of 46 paraffin embedded specimens with no associated clinical outcome data, pAkt staining was positive in 39 (85%) of the samples . radiation sensitivity in vitro. (26) Additional study will be needed to determine whether up front treatment with PI3K or Akt inhibitors will radiosensitize cervical tumors in vivo.
Alternatively, or perhaps in combination, activation of Akt may be a marker of altered glucose metabolism in cervical cancer. In our study, increased expression of pAkt was associated with increased glucose uptake on the pretreatment FDG-PET, suggesting that pAkt expression is associated with tumor glucose uptake in vivo.
To follow up on this result, we tested a series of cervical cancer cell lines for pAkt expression and FDG uptake in vitro. When the PI3K inhibitor LY294002 was used, we observed a decrease in FDG uptake; however, this effect was also present in cell lines that did not overexpress pAkt in the baseline study. It should be noted that our western blots for baseline pAkt were performed in the presence of 25 mM glucose, and there are reports that Akt is activated when cells are exposed to glucose or during glucose uptake. (27, 28) We have observed robust endogenous Akt activation in C33A compared to SiHa and ME-180 cells. We determined that LY294002, a known PI3K inhibitor had a greater effect in SiHa and ME180 than C33A cells. This observation suggests that while LY294002 inhibited Akt mediated glucose uptake in SiHa and ME-180, where the endogenous Akt levels are low, its effect in C33A is limited by preexisting high endogenous phospho-Akt expression and may require a higher dose of LY294002 for the same effect. It is possible that in those cells with no basal Akt activation, presence of glucose may lead to Akt activation and subsequent glucose uptake and that this effect is significantly reduced when PI3K is inhibited. Experiments are ongoing in our laboratory to follow up on these results.
The limitations of this study are those of any gene expression profiling analysis, including the fact that mRNA expression change does not necessarily equate with functional changes to signaling pathways. However, we mitigated this limitation by using 
